Titan Spine and Biomet have signed an agreement that will allow Biomet to distribute Titan Spine’s Endoskeleton line of interbody fusion devices in Germany. The companies will also consider broadening the scope to additional countries within the European Union.
According to a press release, the full line of Endoskeleton devices features Titan’s proprietary implant surface technology—consisting of a combination of roughened topographies at the macro, micro, and cellular levels. The combination of surface levels is designed to create an optimal host-bone response and actively participate in the fusion process by promoting new bone growth, encouraging natural production of bone morphogenetic proteins (BMPs) and creating the potential for a faster and more robust fusion.
Kevin Gemas, president of Titan Spine, said, “Biomet is not only a leader in global spine technology, it shares our philosophy that titanium and engineered surface technology can be used to enhance fusion and bone growth upon implantation of interbody fusion devices, leading to improved patient outcomes. We are pleased to enter into this partnership with Biomet with the goal of bringing Titan Spine devices to more physicians and patients in Europe.”